Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
1995-07-31
2002-05-21
Graser, Jennifer E. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C530S350000, C530S412000, C530S413000, C530S414000, C530S418000, C424S236100
Reexamination Certificate
active
06391315
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a vaccine, as well as isolated antigens and antibodies constituting a composition for inhibiting and preventing induced Staphylococcus infection. More particularly the present invention concerns a vaccine for prevent Staphylococcus infection, its prevention by antibody, therapeutic antibodies and production thereof.
2. Description of Related Art
In the past years, an inactivated vaccine comprising hemolysin and coagulase extracted from a culture medium of
Staphylococcus aureus
was used for treatment of Staphylococcus infections. However, since newly developed antibiotics have also been used for treating Staphylococcus infections, the need for vaccine treatment of Staphylococcus infection has been reduced, and finally the vaccine was no longer used and consigned to lasting oblivion. No development of or ideas for vaccines in this connection have recently appeared. The vaccine for Staphylococcus in the past was not specified as to the effective component, and thus the incomplete combination of purification and undetermined effective component rendered its preventive effect unclear.
Staphylococcus is a Gram-positive bacterium and exists as a normal inhabitant, i.e. indigenous bacterium, of human skin and mucous membrane. Although most strains produce biologically active toxins and enzymes, little is known yet concerning the pathogenesis of Staphylococcal disease which has been markedly aroused in recent years by an apparently increasing incidence of severe illness, particularly in hospital environments where many strains are insensitive to the antimicrobial agents which have so successfully prevented disease mortality by other pyrogenic cocci (
Bacterial and Mycotic Infections of Man,
4th Ed, 1991). On the other hand, conventional Staphylococci vaccines have been tried, namely an autogenous vaccine. Although some doctors have tried this vaccine, its efficacy is yet unclear, because the strain has to be isolated from the patient and inactivated by formalin to prepare the vaccine, and the vaccine thus prepared has to be injected over a long period. This vaccination may inhibit the secondary infection in humans, caused by Staphylococci.
For animals, there is a vaccine in which the whole cells and culture broth are separately inactivated with formalin, and thereafter mixed. This vaccine is to prevent mastitis of animals (Watson D. L.,
Res. Vet. Sci.;
45, 16-21, 1988). For mastitis, the other vaccines are based on highly purified &agr; and &bgr; toxin (
Infect. Immun.,
17, 250-256, 1977) and fibronectin-binding protein (FnBP-A) (
EUR,
294-349, 1988,
Vaccine,
12, 11, 918-922, 1994). It is also known to use a subunit vaccine having components from surface proteins and polysaccharides (T. J. Foster,
Vaccine
9, 4, 221-227, 1991), and synthetic ST enterotoxin comprising 4n to 18n amino acids is said to be useful for inducing in vivo antibodies (U.S. Pat. No. 4,499,080). But these are not vaccines for Staphylococcus infection due to the use of only general vaccine antibody inducing agents.
SUMMARY OF THE INVENTION
In the present invention, a strong &bgr; hemolytic strain, which is a methicillin resistant strain (MRSA in particular) isolated from patients, is cultured in anaerocolumbia agar with rabbit blood (BBL Japan) by the BBL anaerobic jar system. This strain produces component TSST-1 and strong &bgr; hemolysin. After centrifugation of the cultured broth, the supernatant is filtered, ammonium sulfate is added to a concentration of about 65-85% and the resulting precipitate is preserved for later use. The whole cells are immediately suspended in hypertonic buffer solution and are stirred at a temperature below the denaturing point of protein. After centrifugation, ammonium sulphate is added to the cell extract and the resulting precipitate is mixed with the supernatant precipitate. The mixed solution is treated by ion exchange column chromatography to eliminate impurities. The fraction having molecular weight of about 10,000-70,000 is obtained by gel filtration. The main constituents are TSST-1, hemolysin, and enterotoxin, however, this fraction contains neither endotoxin nor whole cells.
The inactivated vaccine of the present invention is thus based in part on the discovery that the antigens have been isolated by mixing the cell surface extract with the supernatant extract. In addition, the preferred strain is a methicillin resistant bacterium isolated from patients showing excellent antigenic activity; moreover, the antigen derived is extracted from the cell wall using a hypertonic buffer solution under mild conditions, and further the specific antigen includes super antigen, major enterotoxins, and the like. The same enterotoxins, for example A, B and C, are produced not only by
Staphylococcus aureus
but also by other species of Staphylococcus. The vaccine derived from the other species contains similar compositions as
Staphylococcus aureus
and may be cross-reactive, and the antibody possesses anti-superantigen neutralizing antibody.
The present invention is therefore directed to a process for producing an antigen preparation for inhibiting or preventing induced Staphylococcal infections in humans, a vaccine containing such an antigen or antigens, and a process for producing antibodies for inhibiting or preventing human and animal infections induced by Staphylococcal compositions containing such antibodies. According to a feature of the present invention, a process for isolating two antigens for preventing or inhibiting human staphylococcal infection comprises separating the whole cells of at least one strain of Staphylococcus from cultured broth, extracting at least some antigens of the cell surface and at least some exotoxin antigens and fractionating the resultant antigen from the extract thus obtained. This vaccine is characterized by containing superantigen (for example TSST-1) and an antibody possessing superantigen neutralizing activity.
REFERENCES:
patent: 4075321 (1978-02-01), Relyveld
patent: 4327082 (1982-04-01), Armitage
patent: 4425330 (1984-01-01), Norcross et al.
patent: 5034515 (1991-07-01), Proctor
patent: 5055455 (1991-10-01), Pier
patent: 5198215 (1993-03-01), De Cueninck
patent: 5240704 (1993-08-01), Tsurumizu et al.
patent: 0 094 997 (1983-11-01), None
patent: 0 163 623 (1985-12-01), None
patent: WO 93/17044 (1993-09-01), None
patent: 9422474 (1994-10-01), None
Braude et al. Infectious Disease & Medical Microbiology, 2nded, 1986. pp. 236-253.*
Rysanek, et al. 1988. Monatshefte fur veterinaermedizin. 43: 58-60.*
Hisanori et al. JICST Accession No: 94A0926646.*
A. Cheung et al., “Surface Proteins ofStaphylococcus aureus”, Reviews of Infectious Diseases, Supplement 2, vol. 10, Jul.-Aug. 1988, pp. 351-355.
L. Sutra et al., “Virulence factors involved in the pathogenesis of bovine intramammary infections due toStaphylococcus aureus”, J. Med. Microbiol., 1994, vol. 40, pp. 79-89.
C. Adlam et al., “Effect of Immunization with Highly Purified Alpha- and Beta-Toxins on Staphylococcal Mastitis in Rabbits”, Infection and Immunity, Aug. 1977, pp. 250-256.
“Treatment of demyelinating disease e.g. multiple sclerosis by administration of detoxified, immunogenically activeStaphylococcus aureus&agr;-toxin; vaccine preparation”, Oct. 1986, US 4,615,884.
D. Watson, “Vaccination against experimental staphylococcal mastitis in ewes”, Research in Veterinary Science, 1988, vol. 45, pp. 16-21.
S. Morse, “Staphylococci and Other Micrococci”, Bacterial and Mycotic Infections of Man, p. 412.
T. Foster, “Potential for vaccination against infections caused by Staphylococcus aureaus”, Vaccine, Apr. 1991, vol. 9, pp. 221-227.
Hashimoto Takashi
Iwai Yuzuru
Sasaki Takeji
Takahashi Takashi
Graser Jennifer E.
Takahashi Hashimoto
Young & Thompson
LandOfFree
Vaccine for inhibiting and preventing induced staphylococcus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine for inhibiting and preventing induced staphylococcus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine for inhibiting and preventing induced staphylococcus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2851781